ANGO

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.

AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4.

AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum.

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics NASDAQ: ANGO reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation.

AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.03 per share a year ago.